Depressive Symptoms Associate With Race and All-Cause Mortality in Patients With CKD

Delphine S. Tuot1,2,3, Feng Lin4, Keith Norris5, Jennifer Gassman6, Miroslaw Smogorzewski7 and Elaine Ku1,3

1Division of Nephrology, University of California, San Francisco; San Francisco, California, USA; 2Center for Vulnerable Populations at Priscilla Chan and Mark Zuckerberg San Francisco General Hospital, University of California, San Francisco, San Francisco, California, USA; 3Kidney Health Research Institute, University of California, San Francisco, San Francisco, California, USA; 4Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, California, USA; 5University of California, Los Angeles, Los Angeles, California, USA; 6Cleveland Clinic Foundation, Cleveland, Ohio, USA; and 7University of Southern California, Los Angeles, Los Angeles, California, USA

Introduction: Depression is common but underrecognized in patients with chronic kidney disease (CKD), especially among racial/ethnic minorities. We examined the association between depressive symptoms and all-cause mortality (including deaths before and after end-stage renal disease [ESRD]) and whether antidepressant use impacts this association, overall, and by race/ethnicity.

Methods: We ascertained whether the presence of depressive symptoms, defined by a Beck Depression Inventory II (BDI) score of >14 at cohort enrollment, was associated with all-cause mortality (before or after ESRD) among study participants of the Chronic Renal Insufficient Cohort (CRIC) overall and by race/ethnicity. Models were adjusted for socioeconomic factors, baseline CKD severity, time-updated comorbid conditions, and time-updated antidepressant use. Confirmatory analyses were performed among African American Study of Kidney Disease and Hypertension (AASK) participants.

Results: Among 3739 CRIC participants, 16.3% had a baseline BDI of >14; 18.2% reported antidepressant use. Crude mortality rate was 3.16 per 100 person-years during 6.8 years of median follow-up. Baseline BDI >14 was independently associated with higher risk of all-cause mortality (adjusted hazard ratio [aHR]: 1.27; 95% confidence interval: 1.07–1.52) without attenuation by antidepressant use. Differences among white and black individuals were noted (Pinteraction = 0.02) but not among white versus Hispanic individuals (Pinteraction = 0.43) or black versus Hispanic individuals (Pinteraction = 0.22). Depressive symptoms were associated with higher mortality among white individuals (aHR: 1.66; 1.21–2.28), but not Hispanic individuals (aHR: 1.47; 0.95–2.28) or black individuals (aHR: 1.06; 0.82–1.37). Similar results were noted among 611 AASK participants (aHR: 0.99; 0.69–1.42).

Conclusions: The presence of depressive symptoms is a risk factor for all-cause mortality among patients with mild-moderate CKD, particularly among white individuals. Further studies are needed to understand the heterogeneity in the response to the presence of depressive symptoms by race.

Kidney Int Rep (2019) 4, 222–230; https://doi.org/10.1016/j.ekir.2018.10.001
KEYWORDS: AASK; chronic kidney disease; CKD; CRIC; depression; mortality
© 2018 International Society of Nephrology. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

See Commentary on Page 189

Depression is common among patients with CKD, with reported prevalence between 20% and 30% compared with 2% to 4% in the general population.1 Similar to the general population, in the CKD population, depression is more common among women, younger individuals, racial/ethnic minorities, those of lower socioeconomic status, and individuals with more comorbid conditions.2 With advancing CKD, the prevalence of depression increases based on either self-report or by interview-based diagnoses,3 with well-recognized higher prevalence of depression among patients with ESRD.4 Despite these data, however, depression is frequently underrecognized among patients with earlier stages of kidney disease who often receive nephrology care in primary care settings, and when recognized, it is often undertreated, particularly among racial or ethnic minorities.2,5

Correspondence: Delphine S. Tuot, Renal Center at Priscilla Chan and Mark Zuckerberg San Francisco General Hospital, 1001 Potrero Avenue, Building 100, Room 342, San Francisco, California 94110, USA. E-mail: Delphine.tuot@ucsf.edu

Received 10 July 2018; revised 23 September 2018; accepted 1 October 2018; published online 9 October 2018
The strength of the association between depression and adverse health outcomes among patients with CKD may not be clear to clinicians who care for most patients with earlier stages of CKD. This may be because most prior studies have examined this issue while considering CKD and ESRD as separate entities, even though CKD and ESRD represent a continuum of kidney disease. For example, among US patients with ESRD, depressive symptoms have been associated with higher risk of cardiovascular events and death, especially if these symptoms are persistent. Among US patients with CKD, depression has been associated with a higher risk of acute kidney injury, progression of kidney disease, and worse cardiovascular outcomes. Data that associate depression with early mortality among patients with CKD are mixed, however, and there are sparse long-term data that demonstrate how presence of depressive symptoms may associate with adverse outcomes. Although some studies have demonstrated an association between depressive symptoms and a higher risk of death, in others, depressed affect was not associated with all-cause mortality.

It is possible that the presence of depressive symptoms during CKD may more strongly associate with mortality after ESRD onset, because patients with depressive symptoms may have poor outcomes if they go on to require dialysis, a life-changing event. One of the few studies that examined the association between depression during the CKD phase of illness and mortality after ESRD found only a weak association in a cohort of US veterans receiving antidepressive therapy. However, only the most severely depressed patients with CKD are likely diagnosed and treated in the clinical setting, so the results of this study may not be widely generalizable to the CKD population.

The objectives of this study were to (i) examine the association between depressive symptoms among patients with CKD and all-cause mortality (including deaths before and after ESRD) in well-characterized cohorts of patients with long-term follow-up, and (ii) determine whether antidepressant use attenuates or strengthens the association between depressive symptoms and death. A secondary objective was to identify whether there are racial or ethnic differences in the association between depression and all-cause mortality given prior evidence that depressive symptoms may associate with outcomes differentially in black and white individuals.

### Materials and Methods

#### Study Sample and Design

We conducted a retrospective cohort study associating depressive symptoms with mortality among participants of the CRIC and the AASK. Between May 2003 and March 2008, CRIC enrolled 3939 adults aged 21 to 74 with mild to moderate CKD (estimated glomerular filtration rate [eGFR] 20–70 ml/min per 1.73 m²). Broadly, exclusion criteria included New York Heart Association class III or IV heart failure, cirrhosis, HIV disease, polycystic kidney disease, prior dialysis therapy or transplant, and current immunosuppressive therapy or chemotherapy. Other inclusion and exclusion criteria have been previously described. For this study, we included only participants who self-identified as white, black, or Hispanic (and excluded those of other race or ethnicity due to small sample size, N = 150). We also excluded participants with missing BDI score at the baseline visit (n = 50).

We included participants from the AASK cohort as a secondary cohort of interest to validate our findings from the CRIC study. The AASK was a 2 × 3 factorial randomized controlled trial that examined the impact of strict blood pressure control and different antihypertensive agents on the progression of CKD among black participants with hypertension-attributed CKD. Between 1995 and 2001, 1094 participants between 18 and 70 years of age with GFR 20–65 ml/min per 1.73 m² were enrolled. At trial closure, 691 participants (87% of eligible participants) who had not developed ESRD or died, continued in the cohort phase of the study, which began in 2002 and ended in 2007. We excluded AASK cohort participants without a baseline BDI (n = 75) and those missing covariates (n = 5).

#### Primary Predictor

We assessed the presence of depressive symptoms at baseline, defined by a BDI II score of >14 at enrollment. The BDI was administered as either a self- or interviewer-administered questionnaire to all CRIC and AASK cohort participants at their baseline visit. The 21-item BDI is a widely used and validated instrument to assess depressive symptoms in patients with and without CKD. The total score range is 0 to 63, with higher scores reflecting more severe depression. A score of greater than 14 has been shown to have reasonable diagnostic accuracy for a clinical diagnosis of depression in CKD.

#### Outcome Ascertainment

The outcome of interest was all-cause mortality (before or after ESRD). Deaths in CRIC were ascertained by report from next of kin, retrieval of death certificates or obituaries, review of hospital records, and linkage with the Social Security Death Index. Deaths among AASK study participants were ascertained based on a combination of trial and cohort data, and linkage to the
Statistical Analyses

In CRIC, unadjusted Cox regression was used to associate baseline depressive symptoms with risk of all-cause mortality (including deaths before or after ESRD). Models were incrementally adjusted for the following potential confounders: sociodemographic factors (age, sex, education [high school graduate yes/no], income, marital status, alcohol, tobacco use) in Model 1; and additional adjustments for baseline eGFR, proteinuria, body mass index, diabetes, and selfreported time-updated comorbid conditions, including cardiovascular disease (myocardial infarction or revascularization), peripheral vascular disease, heart failure, stroke, and hypertension in Model 2; and finally adjustment for self-reported antidepressant use as a time-dependent covariate (Model 3). Supplementary Table S1 lists the antidepressant medications included in this analysis.

For analysis focused on racial differences in mortality among those with and without depressive symptoms, we first tested for interaction between race and ethnicity (categorized as white, black, and Hispanic) and depressive symptoms in the fully adjusted model (Model 2). We identified presence of interaction between white and black participants (Pinteraction black vs. white = 0.02) but not white and Hispanic participants (Pinteraction Hispanic vs. white = 0.43) or black and Hispanic participants (Pinteraction Hispanic vs. black = 0.22). Analyses were then stratified by race/ethnicity. No interaction was identified in Model 3, examining impact of antidepressant use on the relationship between baseline depressive symptoms and mortality. Sensitivity analyses were performed with a baseline BDI > 14 indicating the presence of more severe depressive symptoms. Additional post hoc analyses censored participants at ESRD onset to examine consistency in the association between depression and mortality before and after ESRD.

As confirmatory analysis, we used Cox regression to associate baseline depressive symptoms with risk of all-cause mortality (including deaths before or after ESRD) in AASK. Models were incrementally adjusted for similar potential cofounders as described in Model 1, additionally adjusted for baseline eGFR, baseline proteinuria, cardiovascular disease by self-report, body mass index, cancer, diabetes, and prior randomization assignment (blood pressure target and drug arm) in Model 2, and finally adjusted for baseline antidepressant use (Model 3). Sensitivity analysis was performed using a baseline BDI score of > 16, indicating the presence of more severe depressive symptoms.

RESULTS

Participant Characteristics

Among the 3739 CRIC participants eligible for this study, mean age was 58 (±11) years. Approximately 45% were women and the study population was racially and ethnically diverse (43% white, 43% black, 13% Hispanic). Most CRIC participants had prevalent hypertension, approximately one-half had diabetes, and nearly one-third had cardiovascular disease. Mean eGFR at enrollment was 44 ml/min per 1.73 m² (SD = 15). Individuals with baseline depressive symptoms defined by a BDI > 14 were likely to be younger, female, of nonwhite race/ethnicity, have lower household income, and have more comorbid conditions compared with individuals without depressive symptoms (Table 1). Participants with depressive symptoms were also more likely to have a lower eGFR and proteinuria > 1g/g at baseline. There was no difference in the percentage of participants who progressed to ESRD among those with depressive symptoms (n = 173, 28.2%) and without depressive symptoms (n = 736, 23.5%) at baseline.

Among 611 eligible AASK study participants, mean age was 60 (SD = 10) years. Approximately 38% of participants were women and most had an annual income of less than $40,000. Fewer than 10% of the cohort had diabetes (onset post study entry), although nearly two-thirds had cardiovascular disease. Mean eGFR at enrollment was 39 ml/min per 1.73 m² (SD = 15). Compared with those without depressive symptoms, AASK participants with baseline depressive symptoms were younger, had lower annual household incomes, and were more likely to consume alcohol or be uninsured (Table 2). There was no difference in the percentage of participants who progressed to ESRD in those with (n = 54, 34.6%) and without (n = 135, 30.0%) depressive symptoms at baseline. Compared with black CRIC participants, AASK participants were slightly older, less likely to have health insurance, more likely to have cardiovascular disease but less likely to have diabetes, and self-reported less alcohol use but more tobacco use. Mean eGFR among AASK participants was slightly lower than black CRIC participants (39.2 [± 16.2] vs. 43.6 [± 15.9], P < 0.001) but
Participants (12.2%) (black participants (16.3%) compared with white participants (8.1%) was greater among Hispanic participants (30.5%) and Hispanic individuals (13.5%).

Table 1. Baseline characteristics of Chronic Renal Insufficiency Cohort (CRIC) participants

|                     | No baseline depression, BDI ≤ 14 | Baseline depression, BDI > 14 | P     |
|---------------------|----------------------------------|-------------------------------|-------|
| Age, mean (SD)      | 58.1 (11.1)                      | 55.8 (10.2)                   | <0.001|
| Female sex, n (%)   | 1358 (43.4)                      | 326 (53.2)                    | <0.001|
| Race/ethnicity, n (%) | Non-Hispanic white 1429 (45.7) | 199 (32.5)                    |       |
|                     | Non-Hispanic black 1553 (43.3)   | 263 (42.9)                    |       |
|                     | Hispanic 344 (11.0)              | 151 (24.6)                    |       |
| Annual household income, n (%) | <20,000 868 (27.8) | 329 (53.7)                    | <0.001|
|                     | $20,001–$50,000 788 (25.2)       | 124 (20.2)                    |       |
|                     | $50,001–$100,000 638 (20.4)      | 49 (8.0)                      |       |
|                     | >$100,000 351 (11.2)             | 18 (2.9)                      |       |
| Refuse to answer    | 481 (15.4)                       | 93 (15.2)                     |       |
| Educational attainment, n (%) | Less than high school 591 (18.9) | 216 (35.2)                   |       |
|                     | High school graduate or more 2535 (81.1) | 397 (64.8)                |       |
| Health insurance, n (%) | 2622 (93.0)                      | 456 (88.7)                    | <0.001|
| Medical history, n (%) | Hypertension 2687 (86.0)         | 541 (88.3)                    | 0.13  |
|                     | Congestive heart failure 289 (9.3) | 77 (12.6)                     | 0.01  |
|                     | MI or coronary vasculatization 677 (21.7) | 143 (23.5)                  | 0.32  |
| Cerebrovascular disease | 293 (9.4)                       | 85 (13.9)                     |       |
| Peripheral arterial disease | 197 (6.3)                       | 59 (9.6)                      | 0.003 |
| Diabetes            | 1457 (46.6)                      | 359 (58.6)                    | <0.001|
| Alcohol use, n (%)  | 830 (26.6)                       | 119 (19.4)                    | <0.001|
| Tobacco use, n (%)  | 372 (11.9)                       | 121 (19.7)                    | <0.001|
| BMI category, n (%) | Underweight, BMI < 25 477 (15.3) | 98 (16.0)                     |       |
|                     | Overweight, BMI 25 to < 30 917 (29.4) | 138 (22.6)                  |       |
|                     | Obese, BMI ≥ 30 1725 (55.3)      | 375 (61.4)                    |       |
| eGFR, mean (SD)     | 44.5 (14.9)                      | 42.7 (15.1)                   | 0.006 |
| Urinary PCR ratio ≥ 1 g/g, n (%) | 627 (20.7)                       | 158 (25.8)                    | <0.001|

BMI, body mass index; BDI, Beck Depression Inventory; eGFR, estimated glomerular filtration rate; MI, myocardial infarction; PCR, protein-to-creatinine ratio.

Fewer had proteinuria > 1 g/g (Supplementary Table S2).

Prevalence of Depressive Symptoms and Use of Antidepressants
More than 16% (n = 613) of CRIC participants had a baseline BDI > 14. Prevalence of depressive symptoms was greater among Hispanic participants (30.5%) and black participants (16.3%) compared with white participants (12.2%) (P ≤ 0.01). Overall, 18.3% of CRIC participants reported antidepressant use, with a higher percentage among white (23.5%) compared with black individuals (14.2%) and Hispanic individuals (13.5%) (P < 0.01). More than one-fourth of AASK participants had BDI > 14 and 5.2% self-reported antidepressant use at baseline (Figure 1).

Association of Depressive Symptoms and Mortality
Among all CRIC participants, crude mortality rate was 3.16 per 100 person-years during 6.8 years of median follow-up. Of those who died, nearly 66% (n = 534) died before developing ESRD. Baseline BDI > 14 was associated with higher risk of all-cause mortality before or after ESRD onset (aHR: 1.27; 95% confidence interval 1.07–1.54), even after accounting for sociodemographic variables and comorbid conditions (Model 2, Table 3). Results were similar in the sensitivity analysis using BDI > 16 as a marker of more severe depressive symptoms (aHR: 1.38; 1.15–1.67; Supplementary Table S3) and the analysis that censored individuals at ESRD onset (aHR: 1.29; 1.09–1.54). In all analyses, the relationship between baseline depression and mortality was not attenuated by antidepressant use (Table 3 and Supplementary Table S3).

Baseline BDI > 14 was associated with higher risk of death among white participants (aHR: 1.66; 1.21–2.28),...
a non–statistically significant tendency toward higher mortality risk among Hispanic participants (aHR: 1.47; 0.95–2.29), and was not associated with all-cause mortality among black participants (aHR: 1.06; 0.82–1.37). Similar results were noted when BDI > 16 was used to define the presence of more severe depressive symptoms (Supplementary Table S3). Results were again similar when individuals were censored at ESRD onset, except that presence of depressive symptoms was more strongly associated with higher mortality risk among Hispanic participants (whites individual: aHR: 1.72, 1.29–2.44; Hispanic individuals: aHR: 1.72, 1.10–2.68; black individuals: aHR: 1.04, 0.81–1.34). Adjustment for antidepressant use did not substantially change results in any of the analyses (Table 3 and Supplementary Table S3).

Results of black CRIC study participants were consistent with findings from AASK study participants. AASK participants experienced a crude mortality rate of 3.82 per 100 person-years over a median of 5.1 years of follow-up. Baseline BDI > 14 was not independently associated with greater risk of all-cause mortality (aHR: 0.99; 0.69–1.42), and use of antidepressants at AASK cohort baseline enrollment did not substantially change this association (Table 3). Similar results were noted with BDI > 16 (Supplementary Table S3).

**DISCUSSION**

Depression has been consistently associated with all-cause mortality, adverse cardiovascular health outcomes, and poor quality of life among ESRD populations. This has led to the inclusion of depression screening and follow-up planning in the Centers for Medicare and Medicaid Services ESRD Medicare Quality Incentive Program. Despite studies that have suggested an equally high prevalence of depression among patients with CKD, identification and management of this condition is suboptimal. Although depression among patients with CKD has been associated with worse quality of life and adverse cardiovascular health outcomes, its association with all-cause mortality is still unclear. With this study leveraging long-term follow-up, we provide additional evidence that depressive symptoms among patients with CKD are associated with increased risk of all-cause mortality, including deaths before and after progression to ESRD, and that use of antidepressant medication does not attenuate that risk. This provides additional evidence for the importance of depression identification and new strategies to manage depression among adults with CKD.

The association between depression and mortality among individuals with CKD appears to be stronger among white compared with black or Hispanic individuals (although sample size for the Hispanic subgroup was relatively small, and analyses may be limited in power). We did not find any association between depressive symptoms and all-cause mortality among AASK participants, which is consistent with prior literature. Although depression (defined by either diagnostic codes or having a prescription of an antidepressant medication) was previously found to be strongly associated with increased risk of death among a cohort of white and black patients with CKD, the strength of that association was substantially weaker among black patients. Similarly, no statistically significant association was found between the presence of depressive symptoms (defined by BDI > 14) and
all-cause mortality among AASK cohort participants with CKD during short-term follow-up, although presence of depressive symptoms were associated with a higher risk of cardiovascular events and hospitalizations. In our study, despite additional years of follow-up and enhanced power due to the accrual of a larger number of deaths over this time period, we found BDI > 14 among AASK cohort participants was still not associated with deaths before or after ESRD. Overall, these studies suggest that depressive symptoms are a strong, independent risk factor for mortality among patients with CKD in whites that is not explained by demographic, socioeconomic, or medical factors. In contrast, depressive symptoms do not appear to independently associate with all-cause mortality among blacks with CKD.

Suboptimal understanding of the behavioral and biological mechanisms that explain the link between depression and adverse outcomes (including mortality) may contribute to suboptimal awareness, recognition, and treatment of depression among patients with CKD. Prior proposed mechanisms include the increased self-care demands among patients with multimorbidity (such as those with CKD and ESRD), functional and cognitive impairment that may result from chronic illness, and physical symptoms and biological mechanisms directly related to chronic disease progression and treatments, such as inflammation. None of these mechanisms are known to explain racial/ethnic differences in response to depression, however. Group differences in self-regulatory, stress-coping strategies known to impact health outcomes, such as prayer, social support, exercise, and overeating, could have influenced our findings, but a recent analysis of a subset of 1354 participants in the Health and Retirement Study (mean age = 67) did not find any differences in these behaviors by race/ethnicity. Similarly, nondepressive psychosocial factors were not associated with incident CKD or CKD decline among 3990 participants of the Jackson Heart Study, although mortality was not assessed. Higher of 2 stress resilience genes, glutathione-S-transferase-m1 or GSTM1 and the G allele of FOXO3 in black individuals could account in part for the lack of association between depressive symptoms and mortality among black individuals with CKD, but this remains speculation. Finally, there could be racial/ethnic biases in the depression survey itself. An analysis of college students found no evidence of racial bias in the BDI II survey that was used in this study, but to our knowledge has not been tested among older adult populations with chronic disease and greater racial diversity.

Given the apparent heterogeneity in pathophysiology, consistent and successful treatment of depression to mitigate adverse health outcomes will likely require a comprehensive, multifaceted and multidisciplinary approach. Treatment of depression with antidepressants among patients with chronic illnesses (not CKD) has been shown to improve depressive symptoms and functional status in some studies but not others. The impact of antidepressant use on cardiovascular health and mortality has also been mixed, although evidence for the treatment of depression immediately following a cardiovascular event or as part of a multidisciplinary approach that includes pharmacologic therapy is stronger. Recent trial data suggest that short-term antidepressant use among patients with CKD does not decrease depressive symptoms. Similarly, in our study, exposure to antidepressant use did not attenuate the mortality risk associated with depressive symptoms among white, black, or Hispanic participants. Recent evidence suggests a benefit of cognitive behavioral interventions on depressive symptoms, quality of life, and prescription adherence among patients with ESRD. Studies investigating the impact of a more comprehensive approach (outside of antidepressant medications) to depression treatment, including psychotherapy, among patients with earlier stages of kidney disease are warranted.

### Table 3. Association between baseline BDI > 14 and all-cause mortality, overall and by race

| Number of deaths | Crude mortality rate, per 100 person-years | Unadjusted HR | Model 1 | Model 2 | Model 2 + antidepressant use |
|------------------|------------------------------------------|---------------|---------|---------|-----------------------------|
| **CRIC cohort, n = 3739** | | | | | |
| White individuals, n = 1628 | 815 | 3.16 | 1.64 (1.39–1.94) | 1.47 (1.24–1.75) | 1.27 (1.07–1.52) | 1.27 (1.07–1.51) |
| Hispanic individuals, n = 495 | 301 | 2.58 | 1.82 (1.36–2.43) | 1.89 (1.38–2.60) | 1.66 (1.21–2.28) | 1.67 (1.21–2.30) |
| Black individuals, n = 1816 | 409 | 3.64 | 1.83 (1.24–2.71) | 1.53 (1.00–2.34) | 1.47 (0.95–2.28) | 1.53 (0.99–2.39) |
| **AASK cohort, n = 611** | | | | | |
| White individuals, n = 1628 | 196 | 3.82 | 1.37 (1.08–1.74) | 1.28 (0.99–1.65) | 1.06 (0.82–1.37) | 1.00 (0.77–1.30) |
| Hispanic individuals, n = 495 | 105 | 3.61 | 1.06 (0.77–1.46) | 1.06 (0.75–1.48) | 0.99 (0.68–1.41) | 0.97 (0.67–1.40) |

Model 1 adjusted for age, race/ethnicity, gender, income, marital status, baseline smoking, baseline alcohol (and education in CRIC only).

Model 2 adjusted for model 1 + body mass index category, time-updated comorbid conditions (cardiovascular disease in both cohorts; and congestive heart failure, peripheral vascular disease, stroke, and hypertension in CRIC only) baseline eGFR, baseline proteinuria, baseline diabetes.

AASK models are adjusted also for BP and drug arm assignment.

Associations that are statistically significant with a P value < 0.05 are in bold.

AASK, African American Study of Kidney Disease and Hypertension; BDI, Beck Depression Inventory; CRIC, Chronic Renal Insufficiency Cohort; eGFR, estimated glomerular filtration rate; HR, hazard ratio.

*Statistically significant interaction using white as reference group.
The strength of our study includes the use of a well-characterized cohort that is racially and ethnically diverse. In addition, CRIC provides more than a decade of follow-up of participants and granular data on comorbid conditions, medication use, and laboratory data. The detailed and routine ascertainment of time-updated antidepressant medication use in the CRIC cohort is also a strength. Limitations to our study include its observational nature and reliance on a single measure of depressive symptoms at baseline. We chose not to use time-updated BDI scores due to a large percentage of missing BDI data in later years, potentially contributing to informative censoring. The sample size of Hispanic CRIC participants was relatively small, and thus may be limited in power. In addition, we cannot rule out the presence of residual confounding. We are unable to capture any non-pharmacologic therapy that may have been delivered for treatment of depressive symptoms or depression. We also acknowledge the possibility that use of antidepressants among CRIC participants is a marker of greater attentiveness by providers and/or the provision of more comprehensive cardiovascular care or higher patient vigilance. However, antidepressant use did not attenuate mortality risk in this study.

In conclusion, we found that the presence of depression symptoms strongly associates with mortality risk, both before and after ESRD, particularly in white populations with mild to moderate kidney disease. This adds data about the long-term implications of depression in CKD to existing literature that associates depression symptoms with shorter-term adverse outcomes, such as poor quality of life, and underscores the importance of recognizing depressive symptoms and investigating new strategies to manage depression among adults with CKD. Further studies are needed to understand the heterogeneity in the response to the presence of depressive symptoms by race and ethnicity.

DISCLOSURE
All the authors declared no competing interests.

ACKNOWLEDGMENTS
The AASK Trial and Cohort study was conducted by AASK Investigators and supported by the NIDDK. The data from the AASK Trial and Cohort reported here were supplied by the NIDDK Central Repositories. This article does not necessarily reflect the opinions or views of the AASK Trial and Cohort studies, the NIDDK Central Repositories, or the NIDDK. The interpretation and reporting of the data presented here are the responsibility of the authors and in no way should be seen as an official policy or interpretation of the US government.

This work was supported by the National Institutes of Health through grants K23HL131023 to EK and MD000182, UL1TR000124, and P30AG021884 to KN. EK is also supported by the National Kidney Foundation Young Investigator Award.

Author contributions: Research idea and study design: DST, EK; data analysis/interpretation: DST, KN, EK; statistical analysis: FL, EK; manuscript drafting: DST, KN, EK. Each author contributed intellectual content during manuscript drafting or revision and accepts accountability for the work.

SUPPLEMENTARY MATERIAL
Table S1. Self-reported antidepressant medication use in CRIC.
Table S2. Baseline characteristics of black participants in the African American Study of Kidney Disease (AASK) and Chronic Renal Insufficiency Cohort (CRIC) studies.
Table S3. Association between baseline BDI > 16 and all-cause mortality, overall and by race.

Supplementary material is linked to the online version of the paper at http://www.kireports.org/.

REFERENCES
1. Hedayati SS, Finkelstein FO. Epidemiology, diagnosis, and management of depression in patients with CKD. Am J Kidney Dis. 2009;54:741–752.
2. Fischer MJ, Xie D, Jordan N, et al. Factors associated with depressive symptoms and use of antidepressant medications among participants in the Chronic Renal Insufficiency Cohort (CRIC) and Hispanic-CRIC Studies. Am J Kidney Dis. 2012;60:27–38.
3. Palmer S, Vecchio M, Craig JC, et al. Prevalence of depression in chronic kidney disease: systematic review and meta-analysis of observational studies. Kidney Int. 2013;84:179–191.
4. Cukor D, Cohen SD, Peterson RA, Kimmel PL. Psychosocial aspects of chronic disease: ESRD as a paradigmatic illness. J Am Soc Nephrol. 2007;18:3042–3055.
5. Fischer MJ, Kimmel PL, Greene T, et al. Sociodemographic factors contribute to the depressive affect among African Americans with chronic kidney disease. Kidney Int. 2010;77:1010–1019.
6. Farrokhi F, Abedi N, Beyene J, et al. Association between depression and mortality in patients receiving long-term dialysis: a systematic review and meta-analysis. Am J Kidney Dis. 2014;63:623–635.
7. Kop WJ, Seliger SL, Fink JC, et al. Longitudinal association of depressive symptoms with rapid kidney function decline and
adverse clinical renal disease outcomes. Clin J Am Soc Nephrol. 2011;6:834–844.

8. Hedayati SS, Minhajuddin AT, Afshar M, et al. Association between major depressive episodes in patients with chronic kidney disease and initiation of dialysis, hospitalization, or death. JAMA. 2010;303:1946–1953.

9. Fischer MJ, Kimmel PL, Greene T, et al. Elevated depressive affect is associated with adverse cardiovascular outcomes among African Americans with chronic kidney disease. Kidney Int. 2011;80:670–678.

10. Palmer SC, Vecchio M, Craig JC, et al. Association between depression and death in people with CKD: a meta-analysis of cohort studies. Am J Kidney Dis. 2013;62:483–505.

11. Balogun RA, Abdel-Rahman EM, Balogun SA, et al. Association of depression and antidepressant use with mortality in a large cohort of patients with nondialysis-dependent CKD. Clin J Am Soc Nephrol. 2012;7:1793–1800.

12. Molnar MZ, Streja E, Sumida K, et al. Pre-ESRD depression and post-ESRD mortality in patients with advanced CKD transitioning to dialysis. Clin J Am Soc Nephrol. 2017;12:1428–1437.

13. Feldman HI, Appel LJ, Chertow GM, et al. The Chronic Renal Insufficiency Cohort (CRIC) study: design and methods. J Am Soc Nephrol. 2003;14:S148–S153.

14. Craven JL, Rodin GM, Littlefield C. The Beck Depression Inventory as a screening device for major depression in renal dialysis patients. Int J Psychiatry Med. 1988;18:365–374.

15. Watnick S, Wang PL, Demadura T, Ganzini L. Validation of 2 depression screening tools in dialysis patients. Am J Kidney Dis. 2005;46:919–924.

16. Hedayati SS, Bosworth HB, Kuchibhatla M, et al. The predictive value of self-report scales compared with physician diagnosis of depression in hemodialysis patients. Kidney Int. 2006;69:1662–1668.

17. Hedayati SS, Minhajuddin AT, Toto RD, et al. Validation of depression screening scales in patients with CKD. Am J Kidney Dis. 2009;54:433–439.

18. Ku E, Bakris G, Johansen KL, et al. Acute declines in renal function during intensive BP lowering: implications for future ESRD risk. J Am Soc Nephrol. 2017;28:2794–2801.

19. Ku E, Gassman J, Appel LJ, et al. BP control and long-term risk of ESRD and mortality. J Am Soc Nephrol. 2017;28:671–677.

20. Ku E, Glidden DV, Johansen KL, et al. Association between strict blood pressure control during chronic kidney disease and lower mortality after onset of end-stage renal disease. Kidney Int. 2015;87:1055–1060.

21. Shirazian S, Grant CD, Aina O, et al. Depression in chronic kidney disease and end-stage renal disease: similarities and differences in diagnosis, epidemiology, and management. Kidney Int Rep. 2017;2:94–107.

22. ESRD Quality Incentive Program. Available at: https://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/ESRDQIP/index.html. Accessed April 10, 2018.

23. Abdel-Kader K, Unruh ML, Weisbord SD. Symptom burden, depression, and quality of life in chronic and end-stage kidney disease. Clin J Am Soc Nephrol. 2009;4:1057–1064.

24. Song MK, Ward SE, Hladik GA, et al. Depressive symptom severity, contributing factors, and self-management among chronic dialysis patients. Hemodial Int. 2016;20:286–292.

25. Seidel UK, Gronewold J, Volek M, et al. Psychological, cognitive and emotional factors contributing to quality of life, functional health and participation in community dwelling in chronic kidney disease. PLoS One. 2014;9:e91176.

26. Bugnicourt JM, Godfrey O, Chillon JM, et al. Cognitive disorders and dementia in CKD: the neglected kidney-brain axis. J Am Soc Nephrol. 2013;24:353–363.

27. Katon WJ. Epidemiology and treatment of depression in patients with chronic medical illness. Dialogues Clin Neurosci. 2011;13:7–23.

28. Mezuk B, Ratliff S, Concha JB, et al. Stress, self-regulation, and context: evidence from the Health and Retirement Survey. SSM Popul Health. 2017;3:465–463.

29. Lunyera J, Davenport CA, Bhavsar NA, et al. Nondepressive psychosocial factors and CKD outcomes in black Americans. Clin J Am Soc Nephrol. 2018;13:213–222.

30. Bodonyi-Kovacs G, Ma JZ, Chang J, et al. Combined effects of GSTM1 null allele and APOL1 renal risk alleles in CKD progression in the African American Study of Kidney Disease and Hypertension Trial. J Am Soc Nephrol. 2016;27:3140–3152.

31. Willcox BJ, Tranah GJ, Chen R, et al. The FoxO3 gene and cause-specific mortality. Aging Cell. 2016;15:617–624.

32. Sashidharan T, Pawlow LA, Pettibone JC. An examination of racial bias in the Beck Depression Inventory-II. Cultur Divers Ethnic Minor Psychol. 2012;18:203–209.

33. Lee MC, Wu SV, Hsieh NC, Tsai JM. Self-management programs on eGFR, depression, and quality of life among patients with chronic kidney disease: a meta-analysis. Asian Nurs Res (Korean Soc Nurs Sci). 2016;10:255–262.

34. Katon WJ, Von Korff M, Lin EH, et al. The Pathways Study: a randomized trial of collaborative care in patients with diabetes and depression. Arch Gen Psychiatry. 2004;61:1042–1049.

35. Williams JW Jr, Katon W, Lin EH, et al. The effectiveness of depression care management on diabetes-related outcomes in older patients. Ann Intern Med. 2004;140:1015–1024.

36. Angermann CE, Gelbrich G, Stork S, et al. Effect of escitalopram on all-cause mortality and hospitalization in patients with heart failure and depression: The MOOD-HF randomized clinical trial. JAMA. 2016;315:2683–2693.

37. O’Connor CM, Jiang W, Kuchibhatla M, et al. Safety and efficacy of sertraline for depression in patients with heart failure and depression: results of the SADHART-CHF (Sertraline Against Depression and Heart Disease in Chronic Heart Failure) trial. J Am Coll Cardiol. 2010;56:692–699.

38. Jorge RE, Robinson RG, Arndt S, Starkstein S. Mortality and poststroke depression: a placebo-controlled trial of antidepressants. J Am Psychiatry. 2003;160:1823–1829.

39. Glassman AH, O’Connor CM, Califf RM, et al. Sertraline treatment of major depression in patients with acute MI or unstable angina. JAMA. 2002;288:701–709.

40. Kim JM, Stewart R, Lee YS, et al. Effect of escitalopram vs placebo treatment for depression on long-term cardiac outcomes in patients with acute coronary syndrome: a randomized clinical trial. JAMA. 2018;320:350–358.
41. Katon WJ, Lin EH, Von Korff M, et al. Collaborative care for patients with depression and chronic illnesses. *N Engl J Med*. 2010;363:2611–2620.

42. Hedayati SS, Gregg LP, Carmody T, et al. Effect of sertraline on depressive symptoms in patients with chronic kidney disease without dialysis dependence: the CAST randomized clinical trial. *JAMA*. 2017;318:1876–1890.

43. Cukor D, Ver Halen N, Asher DR, et al. Psychosocial intervention improves depression, quality of life, and fluid adherence in hemodialysis. *J Am Soc Nephrol*. 2014;25:196–206.

44. Lerma A, Perez-Grovas H, Bermudez L, et al. Brief cognitive behavioural intervention for depression and anxiety symptoms improves quality of life in chronic haemodialysis patients. *Psychol Psychother*. 2017;90:105–123.